Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.
Perini GF, et al1; Roberts AW2; Czabotar PE, et al3
Antiapoptotic BCL-2 family members are often found to be variably upregulated in many types of human cancers, such as different subtypes of B-cell lymphoma and solid tumors, and are frequently correlated with decreased susceptibility to chemotherapeutics and increased radioresistance.1 Overexpression of BCL-2 proteins may be an independent indicator of poor prognosis in malignancies including B-cell lymphomas and some solid tumors.1
- Perini GF, et al. J Hematol Oncol. 2018;11(1):65.
- Roberts AW. Hematology Am Soc Hematol Educ Program. 2020;2020(1):1-9.
- Czabotar PE, et al. Nat Rev Mol Cell Biol. 2014;15(1):49-63.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.